Clinical Trial Update: Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase II study evaluating Adebrelimab plus chemotherapy and Apatinib for advanced pulmonary neuroendocrine tumors; trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• Adebrelimab (adebrelimab)
• Apatinib (apatinib)

Snippet

Sponsor: Beijing Chest Hospital | Conditions: Neuroendocrine Tumors | Phase 2 | Status: NOT_YET_RECRUITING